Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Fourth Quarter & Full Year 2025 Results
Fourth quarter and full year 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Press Releases
February 27, 2026
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
February 27, 2026
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
February 24, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Upcoming Events
2Mar
2026
Daiwai Investment Conference 2026 – Tokyo
Conferences
3Mar
2026
UBS European Healthcare Conference – London
Conferences
3Mar
2026
TD Cowen 46th Annual Health Care Conference – Boston
15:10 - 15:40 Fireside chat - EST (Boston)
Conferences
30th Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00